# Cancer Clinic

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/cancer-clinic/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 63 |
| Citations | 218,053 |
| City | Bryan |
| Country | US |
| Description | Cancer Clinic is a research organisation in Bryan, US. OpenAlex records 2,709 works and 218,053 citations for it. 942 researchers list it as their most recent affiliation. |
| Homepage | http://cancerclinic.com/ |
| OpenAlex ID | https://openalex.org/I4210121475 |
| Region | Texas |
| Researchers | 942 |
| ROR ID | https://ror.org/02mfv5g23 |
| Type | healthcare |
| Works | 2,709 |

## University papers

- [Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)](https://scholariq.org/papers/revisions-to-the-staging-and-classification-of-mycosis-fungoides-and-sezary/)
- [Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma](https://scholariq.org/papers/immunomodulatory-drug-cc-5013-overcomes-drug-resistance-and-is-well-tolerated-in/)
- [Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer](https://scholariq.org/papers/clinical-end-points-and-response-criteria-in-mycosis-fungoides-and-sezary/)
- [Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial](https://scholariq.org/papers/mogamulizumab-versus-vorinostat-in-previously-treated-cutaneous-t-cell-lymphoma/)
- [European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas](https://scholariq.org/papers/european-organization-for-research-and-treatment-of-cancer-and-international/)
- [Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model](https://scholariq.org/papers/cutaneous-lymphoma-international-consortium-study-of-outcome-in-advanced-stages/)
- [EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma*](https://scholariq.org/papers/eortc-iscl-and-usclc-consensus-recommendations-for-the-treatment-of-primary/)
- [Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels](https://scholariq.org/papers/association-of-high-tumor-mutation-burden-in-non-small-cell-lung-cancers-with/)
- [Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells](https://scholariq.org/papers/bortezomib-induces-canonical-nuclear-factor-b-activation-in-multiple-myeloma/)
- [Independent Component Analysis Uncovers the Landscape of the Bladder Tumor Transcriptome and Reveals Insights into Luminal and Basal Subtypes](https://scholariq.org/papers/independent-component-analysis-uncovers-the-landscape-of-the-bladder-tumor/)
- [Repair of UV Light-Induced DNA Damage and Risk of Cutaneous Malignant Melanoma](https://scholariq.org/papers/repair-of-uv-light-induced-dna-damage-and-risk-of-cutaneous-malignant-melanoma/)

## University top topics

Showing 8 of 25.

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.